

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces Results for the Third Quarter of 2024

In the third quarter, the company achieved a revenue of 1401.5851 million yuan.

Among them: The cardiovascular implant intervention business achieved a revenue of 517.3834 million yuan, a year-on-year increase of 14.33%. The operating revenue of coronary artery intervention business was 362.5445 million yuan, a year-on-year increase of 7.79%; The operating revenue of structural heart disease business was 135.7549 million yuan, a year-on-year increase of 57.26%. Surgical anesthesia business resumed growth, achieving a revenue of 151.8970 million yuan, a year-on-year increase of 26.99%; The sales of the FDF (Finished Dosage Form) business have stabilized, achieving a revenue of 252.7089 million yuan, and it increased by 1.77% month-on-month and decreased by 63.38% year-on-year.

In the third quarter, the company achieved a net profit attributable to shareholders of the listed company of 105.4136 million yuan, and a net profit attributable to shareholders of the listed company after deducting non recurring gains and losses of 86.9270 million yuan. On the one hand, the company is accelerating its business structure adjustment, continuously focusing on core business, and the large expenses incurred from personnel reset and business reengineering have put pressure on cost control during the period. On the other hand, Shanghai Minwei Biotechnology, the cardiovascular innovation drug company controlled by the company during the year, has made progress in research and development as scheduled this quarter, resulting in a continuous increase in research and development expenses.

In the third quarter, the company achieved a net operating cash flow of 264.1698 million yuan.

During the reporting period, the company achieved a net profit of 783.3477 million yuan, a net profit attributable to shareholders of the listed company of 802.6559 million yuan, and a net profit attributable to shareholders of the listed company after deducting non recurring gains and losses of 734.0744 million yuan.

Financial Results(unaudited)

	Three Months Ended September 30, 2022	% Change	Nine Months Ended September 30, 2022	% Change
Operating revenue(RMB)	1, 401, 585, 073. 03	-28. 41%	4, 785, 471, 627. 57	-23. 55%
Net profit attributable to shareholders of the Company (RMB)	105, 413, 614. 27	-73. 12%	802, 655, 886. 18	-40. 70%
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	86, 927, 048. 85	-77. 19%	734, 074, 379. 16	-42. 91%
Basic earnings per share (RMB /share)	0. 0570	-72. 92%	0. 4339	-40. 30%
Diluted earnings per share (RMB /share)	0. 0570	-72. 92%	0. 4339	-40. 21%
Weighted average rate of return on net assets	0. 66%	Reduce by 1. 80 percentage points	5. 01%	Reduce by 3. 83 percentage points

Full third quarter report

The full three-quarter results report as of and for the nine months ended September 30, 2024 is available on our website at <https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.